Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 574,896 |
|
|||||
| News | - | ||||||
| Day High | 16.26 | Low High |
|||||
| Day Low | 15.32 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.42 | -2.61% | 15.69 | 17:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.01 | 15.32 | 16.26 | 15.69 | 16.11 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,670 | 574,896 | $ 15.77 | $ 9,068,343 | - | 11.83 - 28.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:29:19 | 34 | $ 15.69 | USD |
REGENXBIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 697.51M | 44.43M | - | 90.24M | -263.49M | -5.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
REGENXBIO News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.02 | 19.38 | 15.32 | 17.28 | 430,751 | -3.33 | -17.51% |
| 1 Month | 22.49 | 22.84 | 15.32 | 19.53 | 441,596 | -6.80 | -30.24% |
| 3 Months | 13.43 | 28.80 | 11.83 | 19.41 | 768,729 | 2.26 | 16.83% |
| 6 Months | 16.06 | 28.80 | 11.83 | 18.37 | 647,922 | -0.37 | -2.30% |
| 1 Year | 18.69 | 28.80 | 11.83 | 18.39 | 510,581 | -3.00 | -16.05% |
| 3 Years | 34.83 | 46.46 | 11.83 | 24.72 | 432,515 | -19.14 | -54.95% |
| 5 Years | 50.06 | 55.23 | 11.83 | 30.96 | 443,827 | -34.37 | -68.66% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
